Table 2.

Relative time to composite event of kidney replacement therapy or >50% decline in eGFR

	Model 1		Model 2		Model 3
	RT (95% CI)	p	RT (95% CI)	p	RT (95% CI)	p
SuPAR		<0.001		<0.001		0.05
Quartile 2 vs 1	0.60 (0.44, 0.82)	0.001	0.66 (0.50, 0.88)	0.004	0.75 (0.57, 1.00)	0.05
Quartile 3 vs. 1	0.47 (0.35, 0.64)	<0.001	0.56 (0.42, 0.74)	<0.001	0.71 (0.54, 0.94)	0.02
Quartile 4 vs. 1	0.37 (0.27, 0.51)	<0.001	0.46 (0.34, 0.61)	<0.001	0.67 (0.50, 0.90)	0.008
Age (per 1 y older)	0.92 (0.89, 0.94)	<.001	0.92 (0.89, 0.94)	<.001	0.93 (0.91, 0.96)	<.001
Male sex (v. female)	0.79 (0.64, 0.97)	0.02	0.80 (0.67, 0.96)	0.02	0.77 (0.64, 0.93)	0.005
Black race (vs nonblack)	0.80 (0.64, 1.01)	0.06	0.81 (0.66, 1.01)	0.06	0.75 (0.60, 0.93)	0.008
Hispanic (v. nonHispanic)	0.93 (0.69 1.25)	0.6	1.09 (0.83, 1.43)	0.5	1.08 (0.83, 1.41)	0.6
BMI (per 1 kg/m2 increase)			1.03 (1.01, 1.04)	0.002	1.01 (0.99, 1.03)	0.2
SBP				0.05	1	0.06
≤ 50th percentile			1.00 (reference)	--	1.00 (reference)	--
50th-90th percentile			0.94 (0.76, 1.15)	0.5	0.98 (0.79, 1.20)	0.8
> 90th percentile			0.75 (0.59, 0.95)	0.02	0.77 (0.60, 0.98)	0.03
Antihypertensive use			0.85 (0.70, 1.04)	0.1	0.89 (0.73, 1.09)	0.3
Proteinuria				<0.001		<0.001
< 0.5 mg/mg			1.00 (reference)	--	1.00 (reference)	--
0.5–<2.0 mg/mg			0.65 (0.54, 0.80)	<0.001	0.71 (0.58, 0.86)	0.001
≥2 mg/mg			0.37 (0.29, 0.49)	<0.001	0.42 (0.32, 0.54)	<0.001
Glomerular diagnosis (v. non-glomerular)			0.89 (0.72, 1.12)	0.3	0.76 (0.60, 0.95)	0.02
eGFR (per 10 mL/min/1.73m2 lower)					0.81 (0.76, 0.86)	<.001

based on lognormal parametric survival models among 521 participants contributing 171 events.

Model 1: Minimally adjusted: age, sex, race

Model 2: Model 1 plus BMI, hypertension (systolic BP percentiles), antihypertensive use, proteinuria, glomerular diagnosis

Model 3: Model 2 plus eGFR